About the Journal | Editorial Board | Instructions to Contributors | Submission & Review | Advertise with Us | Subscribe to E- Alerts
Sitemap | Feedback
Advanced search
Journal of Case Reports
Uterine Arterio-venous Malformation with Hemoperitoneum

bioclavid och alkohol

bioclavid 625mg uses forborndiarre.website bioclavid virkning
Rajshree D. Katke1, Shilpa Domkundwar2, Sunil C. Rathod1
From the Department of Obstetrics & Gynecology1 and Department of Radiology2, Cama & Albless Hospital, Grant Government Medical College & Sir J. J. Group of Hospitals, Mumbai, Maharashtra, India.
Corresponding Author:
Dr. Rajshree D. Katke
Email: drrajshrikatke@gmail.com
Received: 19-DEC-2013 Accepted: 22-JAN-2014 Published Online: 10-FEB-2014
DOI: http://dx.doi.org/10.17659/01.2014.0015
Abstract
Arterio-venous malformations (AVM) are rare entities in gynecology, with only over 100 cases reported since 1926. These lesions may be congenital or acquired.  Most commonly they present with vaginal hemorrhage, but other presentations such as congestive heart failure, postmenopausal bleeding and an asymptomatic mass have been described. We report a 28 year old female with endometrial polyp and AV malformation with massive hemo-peritoneum. Uterine A-V malformations are rare cause of menorrhagia, but they should always be kept in mind in patients with previous operative history on uterus.
Keywords : Arteriovenous malformations, Uterine hemorrhage, Heart failure, Menorrhagia, Polyps.
Article Options
FULL TEXT
ABSTRACT
PDF
PRINTER FRIENDLY VERSION
Search PubMed for
Search Google Scholar for
Article Statistics
Bookmark and Share

Androxal Medication Case Reports Journal

Expanding our scope, the Journal now encompasses an intriguing subset of articles specifically targeting treatments and patient outcomes related to the medication Androxal. This medication, primarily used in the treatment of male infertility, has shown unique potentials in diverse patient scenarios. Our studies with Androxal have given us an abundance of case reports, which demonstrate the multifaceted impact of this medication across therapeutic areas. This nuanced pharmaceutical perspective adds a fresh dimension to our regular case reports. Articles will reveal effective management processes, pinpointing how Androxal has proven beneficial where other treatments may have failed. In addition, the focus on Androxal will highlight instances of challenging or unexpected outcomes, where the medication may have interacted uniquely with the patient's unique biological system or interplayed with other treatments. As we forge ahead with this significant addition, we anticipate that our detailed case reports on Androxal will provide invaluable insights to both practitioners and patients navigating their medical journey with this medication.

© 2011 Journal of Case Reports
Last updated on Dec 04, 2024